Search

GlaxoSmithKline PLC

Затворен

СекторЗдравеопазване

1,389.5 -0.22

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1378.5

Максимум

1397

Ключови измерители

By Trading Economics

Приходи

559M

501M

Продажби

105M

8.1B

P/E

Средно за сектора

21.557

57.333

EPS

23.2

Дивидентна доходност

4.79

Марж на печалбата

6.172

Служители

68,629

EBITDA

-52M

1.1B

Препоръки

By TipRanks

Препоръки

Неутрален

12-месечна прогноза

+13.6% upside

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

4.79%

2.63%

Следващи печалби

30.04.2025 г.

Следваща дата на дивидент

10.07.2025 г.

Следваща дата на екс-дивидент

15.05.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-5.9B

54B

Предишно отваряне

1389.72

Предишно затваряне

1389.5

GlaxoSmithKline PLC Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

9.04.2025 г., 09:39 ч. UTC

Значими двигатели на пазара

Pharma Stocks Tumble After Trump Threatens Tariffs on Medicines

5.02.2025 г., 11:32 ч. UTC

Печалби

GSK Launches $2.5 Billion Buyback, Raises Midterm Sales Outlook -- 2nd Update

5.02.2025 г., 08:56 ч. UTC

Печалби

Correction to GSK Article

5.02.2025 г., 08:24 ч. UTC

Печалби

GSK Issues $2.5 Billion Buyback, Raises Midterm Outlook After Beating Market Views -- Update

5.02.2025 г., 07:43 ч. UTC

Печалби

GSK Expects Further Profit Growth After Beating Market Views

23.04.2025 г., 21:48 ч. UTC

Топ новини

Shingles Vaccine Appears to Lower Dementia Risk -- WSJ

23.04.2025 г., 20:47 ч. UTC

Топ новини

Shingles Vaccine Appears to Lower Dementia Risk -- WSJ

23.04.2025 г., 20:40 ч. UTC

Топ новини

Shingles Vaccine Appears to Lower Dementia Risk -- WSJ

15.04.2025 г., 09:55 ч. UTC

Пазарно говорене

U.S Pharma Import Probe Clouds Clarity for EU Companies -- Market Talk

9.04.2025 г., 07:23 ч. UTC

Пазарно говорене

Pharma Stocks Tumble After Trump Floats Tariffs on Industry -- Market Talk

3.04.2025 г., 08:41 ч. UTC

Пазарно говорене

Big Pharma Left Uncertain About U.S. Tariff Risk -- Market Talk

3.04.2025 г., 08:36 ч. UTC

Пазарно говорене

U.K. Pharma to Have Some Share-Price Volatility But Long-Term Outlook Remains Intact -- Market Talk

3.04.2025 г., 07:51 ч. UTC

Пазарно говорене

Big Pharma Stocks Rise After Exclusion From U.S. Tariffs -- Market Talk

2.04.2025 г., 09:27 ч. UTC

Горещи акции

Stocks to Watch Wednesday: Tesla, Newsmax, Novo Nordisk -- WSJ

26.03.2025 г., 22:29 ч. UTC

Топ новини

U.S. Prosecutors Probe Tip About Timing of Pfizer Vaccine -- 2nd Update

26.03.2025 г., 19:19 ч. UTC

Топ новини

U.S. Prosecutors Probe Tip About Timing of Pfizer Vaccine -- Update

26.03.2025 г., 17:39 ч. UTC

Топ новини

U.S. Prosecutors Probe Tip About Timing of Pfizer Vaccine -- WSJ

19.03.2025 г., 14:50 ч. UTC

Топ новини

HIV Drug Makers Get Spooked by Trump Cuts, but Impact Looks Manageable -- Heard on the Street -- WSJ

17.03.2025 г., 09:00 ч. UTC

Топ новини

Pfizer Has a New Playbook for Reviving Sales -- And It's Starting to Pay Off -- WSJ

24.02.2025 г., 07:05 ч. UTC

Придобивния, сливания и поглъщания

GSK Completes Acquisition of IDRx

14.02.2025 г., 11:38 ч. UTC

Топ новини
Печалби

Moderna's Results Reaffirm a Grim Picture for Vaccine Maker -- Barrons.com

14.02.2025 г., 11:30 ч. UTC

Топ новини
Печалби

Moderna's Results Reaffirm a Grim Picture for Vaccine Maker -- Barrons.com

5.02.2025 г., 15:33 ч. UTC

Пазарно говорене
Печалби

GSK's Pipeline Has to Prove It Can Counter Concerns Over Vaccine Business -- Market Talk

5.02.2025 г., 08:38 ч. UTC

Пазарно говорене
Печалби

GSK Needs to Show It Can Navigate Vaccines Challenge -- Market Talk

5.02.2025 г., 07:05 ч. UTC

Печалби

GSK PLC Had Seen 2031 Sales Outlook at More Than GBP38B

5.02.2025 г., 07:04 ч. UTC

Печалби

GSK PLC Sees 2031 Sales Outlook at More Than GBP40B

5.02.2025 г., 07:03 ч. UTC

Печалби

GSK PLC Sees 2025 Adjusted EPS Growth of 6%-8%

5.02.2025 г., 07:03 ч. UTC

Печалби

GSK PLC Raises Mid-Term View

5.02.2025 г., 07:03 ч. UTC

Печалби

GSK PLC Sees 2025 Adjusted Operating Growth of 6% - 8%

5.02.2025 г., 07:02 ч. UTC

Печалби

GSK PLC Sees 2025 Turnover Growth of 3% to 5%

GlaxoSmithKline PLC Прогноза

Ценова цел

By TipRanks

13.6% нагоре

12-месечна прогноза

Среден 1,583.64 GBX  13.6%

Висок 2,290 GBX

Нисък 1,350 GBX

Според 11 анализатори от Wall Street, предложили 12-месечна ценова цел за GlaxoSmithKline PLC през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

11 ratings

1

Купи

8

Задържане

2

Продай

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно GlaxoSmithKline PLC

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; two strategic collaborations with Relation to advance therapeutics for fibrotic diseases and osteoarthritis; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.